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Abstract. 7B2, a protein initially isolated from the porcine 
pituitary gland, has been identified in numerous animal 
and human tissues, with the highest concentrations in the 
pituitary and hypothalamus. The 7B2 molecule is highly 
evolutionarily conserved and is considered to be indispens-
able in the function and regulation of proprotein convertase 2 
(PC2). In the present study, the plasma 7B2 immunoreactivity 
(7B2-IR) of 18 patients with liver disease was studied. Of 
these patients, seven (three male and four female), aged 37-67 
[54.6±13.5 (SD)] years, suffered from liver cirrhosis of cryp-
togenic (n=2) or alcoholic (n=5) aetiology. The remaining 11 
patients (four male and seven female), aged 22-76 [56.1±17.6 
(SD)] years, suffered from miscellaneous liver abnormalities. 
The clinical diagnosis was confirmed in the majority of patients 
by the histological examination of a percutaneous liver biopsy 
or by appropriate radiological investigations. Plasma bilirubin, 
alkaline phosphatase, aspartate aminotransferase, albumin, 
prothrombin time, electrolytes, urea and creatinine were 
measured. The plasma 7B2-IR levels were estimated using a 
sensitive radioimmunoassay (RIA), and the elution position 
of 7B2-IR was verified by gel chromatography. The mean 
plasma 7B2-IR concentration in patients with liver disease 
was 99.44±15.9 pmol/l. In the patients with hepatocellular 
damage due to metastatic tumours [Ca bronchus, carcinoid 
(n=6)], the 7B2‑IR concentrations were significantly higher 
[185±36.9 pmol/l, (P<0.05)] compared with the overall subjects 
with liver damage. The results of the present study demonstrate 
that 7B2-IR is increased in liver disease, with the highest levels 
detected in patients with tumourous liver conditions.
Introduction
The liver is central to body metabolism and when it is affected 
by diseases, such as cirrhosis, its complex functions are 
invariably impaired. Changes in the metabolism of several 
hormones have been observed in liver disease.
It was reported that 8 to 68% of 44 patients with hepa-
tocellular carcinoma had increased levels of α‑ and β-human 
chorionic gonadotropin (hCG) subunits, calcitonin, parathy-
roid hormone (PTH), prolactin (PRL), adrenocorticotropic 
hormone (ACTH) and growth hormone (GH). Due to the 
simultaneous increases of these hormones in cirrhosis, 
their production is likely to be due to the metabolic effects 
of liver cell dysfunction rather than ectopic production (1). 
Corticotrophin releasing hormone (CRH) has been shown to 
be secreted by NPL-KC (a human hepatoma cell line) and 
behave as a hypothalamic CRH (2). CRH and ACTH were 
observed to be produced by liver and lung metastases in a 
patient with a pituitary carcinoma and the clinical presentation 
of Cushing's disease (3).
In males with liver cirrhosis, a reduction in free testos-
terone in the serum was shown to be associated with normal 
basal lutenising hormone (LH) and follicle-stimulating 
hormone (FSH), suggesting impaired function of the hypotha-
lamic-pituitary-gonadal axis (4). The low testosterone level and 
the derangement of the hypothalamic-pituitary function have 
a role in the sexual dysfunction and changes in sex hormones 
that occur in male patients with cirrhosis (5). The LH levels 
of amenorroeic females with various aetiologies of cirrhosis 
were shown to have decreased below the normal range in 50% 
of patients with alcoholic cirrhosis and 42% of patients with 
non-alcoholic cirrhosis, and tests revealed that the hypothal-
amus, rather than the pituitary, was the site of the disturbance 
in gonadotrophin secretion (6). Gonadotrophin-releasing 
hormone (GnRH) receptors have been localised in various 
differentiated hepatocarcinoma tissues and their expression in 
these tissues is associated with the degree of differentiation (7). 
Treatment with a combination of sex hormone suppression and 
inhibition of their target receptors has been attempted in the 
tissues of patients with hepatocellular carcinoma (8,9).
In patients with cirrhosis, the hypothalamic-pitu-
itary-adrenal and -gonadal axes and PRL secretion are 
impaired. The response of GH to GH-releasing hormone 
(GHRH) is also accelerated, and elevated basal and stimulated 
levels of GH possibly reflect compensation for the low levels 
of IGF-1, which is associated with deteriorating liver func-
tion (8). No effects of the aetiology of cirrhosis on the degree 
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of alteration of the hypothalamic-pituitary glandular axes have 
been observed (10,11).
Serum ghrelin, tumour necrosis factor (TNF)-α and inter-
leukin 6 (IL6) levels have been reported to be significantly 
higher in cirrhosis and hepatocellular carcinoma patients, 
whereas serum leptin levels were observed to be decreased 
(12). Amphiregulin (AR), a member of the epidermal growth 
factor family has been shown increased in liver cirrhosis and 
behaves as a potent pro-regenerative and survival factor (13). 
Neurotensin (NT) is expressed in the human fetal liver, but 
not in the adult; in the fibrolamellar carcinoma, (NT) is also 
expressed but not expressed in the regerating rat liver (14). 
Somatostatin (SRIH), cortistatin and SRIH receptor subtypes 
are present in rat Kupfer cells where they may function in an 
autocrine manner (15). SRIH analogs (SSTs) have produced 
promising results for the treatment of hepatocellular cancer 
and a long-acting SST analog (lanreotide; LAN) exhibited 
the ability to decrease the S-phase fraction, as well as induce 
apoptosis in HepG2 cells in a dose-dependent manner (16). 
Peptide 23, a newly identified protein by rat pituitary cells, is 
stimulated by GH and inhibited by SRIH.  Peptide 23-cDNA 
has ~73% homology with human hepatocellular carcinoma 
cDNA from human hepatocellular carcinoma (17). 
The majority of liver tumours express cholecystokinin 
(CCK-B) receptors and are able to process gastrin (G) as far as 
pro-G and G-gly (precursor forms) and this may be associated 
with tumour proliferation (18). Gut hormone receptors are 
overexpressed in human cancer and allow receptor-targeted 
tumour imaging and therapy. A novel promising receptor 
for these purposes is the secretin receptor. Secretin recep-
tors are expressed in the human liver particularly the biliary 
tract and cholangiocarcinomas but not the hepatocytes or 
hepatocellular carcinomas (19). Hepatic failure is associated 
with increased pancreatic glucagon levels (true hyperglucago-
naemia is suppressed by glucose) (20). Methionine enkephalin 
and other opioid peptides have been shown to be increased in 
both cirrhosis and acute liver disease (21). Furthermore, there 
is evidence that the central mechanism involved in the brain-
liver interaction in the development of symptoms of hepatic 
encephalopathy (such as pruritus and fatigue) involves the 
opioid system (22). A class of endogenous opioids is upregu-
lated in liver disease particular to cholestasis, which contribute 
to pruritus, hypotension and encephalopathy. Symptoms asso-
ciated with cholestasis are reversed or ameliorated by opioid 
receptor antagonists. Opioid receptor antagonists have been 
reported to relieve multiple symptoms, except for pruritus, 
and improve liver function as demonstrated in experimental 
cholestasis (23).
7B2 was identified in 1982 by Seidah et al during the 
purification of the N‑terminal glycol‑segment of proopiomela-
nocortin (POMC) from pig anterior pituitaries (24). Later, 
the same investigators reported the purification of its human 
pituitary homologue (25). The two sequences differed by only 
one amino acid. 7B2 cDNA cloning from various species has 
demonstrated the high evolutionary conservation of the 7B2 
molecule, suggesting that 7B2 may be biologically relevant. 
In particular, the overall residue identity is extremely high 
(90-96%) among mammals, relatively high (67-83%) between 
mammals and frogs or fish, and low (17‑22%) between verte-
brates and invertebrates (26,27). Initially, 7B2 was revealed 
to be located in the pituitary gonadotrophs (26,27) and to 
respond to exogenous LH-releasing hormone (LHRH) (26). 
7B2 has also been demonstrated to be located in tissues that 
are primary neuronal (the brain and adrenal medulla) or 
endocrine (pituitary, thyroid and pancreas) tissues, or those 
that are known to carry a sub-population of neuroendocrine 
cells (gastrointestinal tract). The highest levels are detected in 
the anterior lobe of the pituitary, followed by the neurointer-
mediate lobe, hypothalamus, adrenal medulla, thyroid gland 
and pancreas (27). In cell cultures (normal pituitary cells), 
the secretion of 7B2 appears to be unaffected by GHRH and 
CRH, but is increased by LHRH (26,27).
7B2 is detectable in human plasma. It is present at remark-
ably high levels in early childhood, which gradually decrease 
to adult levels by 20 years of age and slowly rise again with 
aging (28,29). The levels of 7B2 are elevated in pregnancy, 
from the second to the fourth trimester, but sharply decline 
soon after delivery and return to normal by 4-6 weeks 
post-partum (30). Initial studies of plasma 7B2 level increases 
in patients suffering from chronic kidney failure and liver 
cirrhosis (28,29,31) have suggested that these organs are 
involved in 7B2 clearance.
In the present study, the plasma 7B2 immunoreactivity 
(7B2-IR) levels were measured in patients with liver disease, 
mainly cirrhosis of various aetiologies, in a further attempt to 
investigate the hepatic handling of this protein.
Patients and methods
Patients. The present study was also undertaken by 
Dr L. Meleagros (Endocrine Unit, Hammersmith Hospital, 
London, UK). In total, 18 patients with liver disease, who 
were under the care of Dr J. Calam (Department of Medicine, 
Hammersmith Hospital), were studied. The study was approved 
by the Ethics Committee of Hammersmith Hospital (RPMS, 
Imperial College London) and written informed consent 
was obtained by the patients. Of these patients, seven (three 
male and four female), aged 37-67 [54.6±13.5 (SD)] years 
and weighing 51-96 [69.5±17.8 (SD)] kg, suffered from 
liver cirrhosis of cryptogenic (n=2) or alcoholic (n=5) 
aetiology. The remaining 11 patients (four male and seven 
female), aged 22-76 [56.1±17.6 (SD)] years and weighing 
50-100 [67.7±14.8 (SD)] kg, suffered from miscellaneous liver 
abnormalities.
The clinical diagnosis was confirmed in the majority of 
patients by the histological examination of a percutaneous liver 
biopsy or by appropriate radiological investigations (Table I). 
The total number of patients and the numbers with jaundice, 
ascites/oedema and hepatic encephalopathy are also shown in 
Table I.
The medication received by the patients was as follows 
(number of patients with cirrhosis vs. without cirrhosis): 
folic acid (6 vs. 0), ranitidine (5 vs. 0), prednisolone (1 vs.2), 
vitamin K (3 vs. 0), parentrovite (2 vs. 1), lactulose (4 vs. 0), 
diuretics (0 vs. 2), heparin (0 vs.1), cyclosporin A (1 vs. 0), 
salazopyrine (0 vs. 1), insulin (0 vs. 1), neomycin (1 vs. 0) 
and cyproheptadine (0 vs. 1). In addition three patients with 
and one without cirrhosis were on protein-restricted diets, 
and three cirrhotic patients were on salt-restricted diets. 
Peripheral venous blood samples were obtained between 
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08:00-09:00 hours with the patients in a seated position. 
All medication was withheld on the morning of the study. 
Samples were collected in heparinised tubes for the plasma 
7B2-IR estimations and were processed as described. The 
plasma samples (100 µl aliquots) were assayed for 7B2-IR in 
duplicate. Plasma bilirubin, alkaline phosphatase, aspartate 
aminotransferase, albumin, prothrombin time, electrolytes, 
urea and creatinine were measured at the Chemical Pathology 
Laboratory of Hammersmith Hospital.
7B2 radioimmunoassay (RIA). A sensitive RIA for 7B2-IR 
was developed in our laboratory as described previously (32).
Immunisation and preparation of antisera. A peptide 
fragment corresponding to residues 23-39 of the authentic 
180 amino acid 7B2 molecule was custom synthesised 
(Cambridge Research Biochemicals, Cambridge, UK) and 
conjugated to bovine serum albumin (BSA; Sigma Chemical 
Co., Dorset, Poole, UK) by carbodiimide. The conjugated 
material was emulsified in complete Freund's adjuvant for 
the primary immunisation and in incomplete adjuvant for the 
booster injections. Freund's adjuvant was prepared by mixing 
8.5 ml n-hexadecane (Koch-Light Laboratories Ltd.) with 
1.5 ml Arlasel A (Sigma Chemical Co.) and was then completed 
by the addition of heat-killed mycobacteria (1 mg/ml).
Emulsified conjugate (2 ml) containing 80 pg conjugated 
peptide was administered to New Zealand white rabbits via 
0.5 ml subcutaneous injections, one into each groin and axilla. 
At three months subsequent to the primary immunisation, 
booster injections were administered at two‑monthly intervals. 
Each injection contained 40 µg conjugated 7B2 (23‑39) in 2 ml 
incomplete Freund's adjuvant (i.e. without mycobacteria). The 
rabbits were bled from the marginal ear vein seven to ten days 
after each booster injection. Blood was allowed to clot at room 
temperature and the serum was separated by centrifugation. 
Each harvested serum sample was then evaluated for its ability 
to bind 125I-7B2 (23-39). For this test, 20 µl undiluted serum 
was added to each assay tube (in duplicate) containing assay 
buffer and label to a total volume of 700 ml.
The antisera that exhibited >70% binding after 1 h of 
incubation at room temperature followed by charcoal/dextran 
separation were subsequently tested at three dilutions in order 
to determine the optimal working dilution. The antiserum used 
in these studies was labelled AG7 and used at a final dilution 
of 1/160,000, with an affinity constant of 1.9x1011 l/mol with 
respect to the synthetic fragment. The antibody was shown 
to cross-react by 33% with authentic porcine 7B2 on a molar 
basis. Νo cross‑reactivities were observed with human insulin, 
proinsulin, glucagon, secretin, SRIH, human pancreatic poly-
peptide, ACTH, N-terminal of POMC, β-lipoprotein (LPH), 
β-endorphin, GH, arginine vasopressin (AVP), oxytocin, ovine 
corticotrophin releasing factor (oCRF) and vasoactive intes-
tinal peptide (VIP).
Iodination procedure. The synthetic fragment 7B2 was used 
for the preparation of (125I-Tyr4)-7B2 (23-39) by the standard 
chloramine T method (33).
Standards. The standards were prepared gravimetrically using 
the synthetic 7B2 fragment. Aliquots (10 µl), each containing 
2 pmol 7B2 (23-39), were lyophilised to 10-2 torr and stored 
in vacuo at -20˚C.
Assay conditions. All samples were assayed in duplicate in 
2-ml polysterene tubes (LKB, Luckham Ltd.). A total of 100 µl 
of the sample was added to each assay tube. Phosphate buffer 
(0.4 ml of 0.6 M, pH 7.4), containing 10 mM EDTA, 7.5 mM 
sodium azide and 150 mM BSA was used as the assay buffer. 
The label and antiserum were made up in the same buffer and 
100 µl of each was added to each assay tube to give a final 
volume of 700 µl.
Separation. Subsequent to a five‑day incubation at 4˚C, the 
antibody-bound label was separated from the free label by 
adding 250 µl of a suspension containing 4 mg charcoal (Norit 
GSX; Hopkin and Williams) coated with 0.4 mg clinical grade 
dextran (Sigma Chemical Co.) to each tube. The tubes were 
centrifuged at 1600 x g for 20 min at 4˚C and the supernatant 
was aspirated immediately.
Gamma counting. Following separation, the charcoal pellet 
and supernatant were counted in multi-well gamma counters 
Table I. Characteristics of patients with liver disease.
Diagnosis Total no. His Rad Jaun Asc/Oed Enc
Cirrhosis  7 4 3 5 3 5
Primary sclerosing 1 1 1 0 0 0
cholangitis
Hepatic metastases 6 6 6 1 1 0
Budd-Chiari syndrome 1 1 1 0 0 1
Fatty liver 1 1 1 0 0 0
Amyloid disease 1 1 0 0 0 0
Cholelithiasis 1 0 1 1 0 0
Clinical features of 18 patients with liver disease. The columns indicate the number of patients, i.e. total in each group; His, patients in whom 
the clinical diagnosis was confirmed histologically; Rad, patients in whom the clinical diagnosis was confirmed by radiological investigations; 
Jaun, patients with jaundice; Asc/Oed, patients with ascites and oedema; Enc, patients with hepatic encephalopathy.
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(NE 1600; Nuclear Enterprises). Since synthetic 7B2 (23-39) 
was used as a standard, the results are expressed as 7B2 immu-
noreactive equivalents (7B2-IE).
7B2-IE changes per 0.9 fmol/assay tube were detected with 
95% confidence limits, with intra‑ and inter‑assay variations 
of <15%.
Chromatographic profiles. Samples containing 7B2-IE were 
subjected to gel permeation chromatography. A 1.4x90‑cm 
column of Sephadex G-100 was used to separate the compo-
nents present in the plasma.
The column was eluted with a 0.06 M phosphate buffer 
(pΗ 7.4) containing 10 mM EDTA, 0.3% BSA and 0.2 M 
NaCl, at a flow rate of 3.2 ml/h at 4˚C.
The column was pre-calibrated with dextran blue [molec-
ular weight (MW), 2,000,000], horse heart cytochrome C 
(MW, 12,384) and a trace amount of NaI125. Dextran blue, 
cytochrome C and a trace amount of NaI125 were added to each 
sample as internal markers. The elution coefficient (Kav) for 
each immunoreactive peak was calculated according to the 
method used by Laurent and Killander (34). Gel permeation 
chromatography of porcine pituitary extracts showed a major 
peak (90% of total immunoreactivity), eluting prior to cyto-
chrome C (32).
Statistical analysis. Statistical analyses were performed using 
two-tailed t-tests. P<0.05 was used to indicate a statistically 
significant difference.
Results
Patients. The results of the liver function tests and plasma 
biochemistry in the patients with and without cirrhosis are 
presented in Table II. Among the cirrhotic patients, signifi-
cantly raised plasma bilirubin and aspartate aminotransferase 
levels, a prolonged prothrombin time and a reduced plasma 
albumin level provided evidence of hepatocellular damage and 
impaired liver function. Among the non-cirrhotic patients, the 
Table II. Plasma biochemistry and coagulation status in patients with liver disease.
Variable Cirrhotic Non-cirrhotic P-value
Bilirubin 203.1±81.7 32.4±14.8 <0.02
(2-14 µmol/l) (12-564) (3-140)
Alkaline phosphatase 270.9±64.3 477.8±125.3 ns
(30-130 IU/l) (145-642) (82-1062)
Aspartate aminotransferase 167.3±41.6 57.7±13.8 <0.01
(10-35 U/l) (38-361) (18-98)
Albumin 30.3±3.1 38.2±1.7 <0.05
(35-55 g/l) (22-46) (33-50)
Prothrombin time 20.7±2.2 15.2±0.5 <0.05
(11-15 seconds) (14-29) (13-16)
Sodium 135.6±2.8 138.4±0.8 ns
(136-149 mmol/l) (121-142) (134-142)
Potassium   3.9±0.2 4.3±0.2 ns
(3.8-5.2 mmol/l) (3.1-4.7) (3.5-5.2) 
Bicarbonate 24.1±0.8 25.0±1.2 ns
(24-30 mmol/l) (20-26) (18-30)
Urea   7.3±2.0 5.3±1.2 ns
(2.5-6.5 mmol/l) (2.1-17.1) (2.9-16.4)
Creatinine 148.4±46.8 85.9±4.3 ns
(55-125 pmol/l) (53-394) (53-150)
Liver function tests and plasma biochemistry in patients with cirrhotic (n=7) and non-cirrhotic (n=11) liver disease. Normal ranges and units 
are in brackets in the variable column. Results are expressed as the mean ± SEM with the range in brackets. P‑value shows the significance of 
differences between the groups. ns, not significant.
Figure 1. 7B2 concentrations in patients with liver disease of various aeti-
ologies compared with those observed in patients with liver disease due to 
metastatic tumours. *P<0.05 vs. A.
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plasma bilirubin level was slightly raised, since 2 patients in 
this group (one with hepatic metastases and one with chole-
lithiasis) had common bile duct obstruction. This group had 
a higher, although not statistically significant, mean alkaline 
phosphatase level compared with the cirrhotic group, due to 
intrahepatic (two patients with primary sclerosing cholan-
gitis and one with amyloid infiltration) or extra‑hepatic (one 
patient with hepatic metastases and one with cholelithiasis) 
cholestasis. However, the aspartate aminotransferase level was 
only marginally increased, while the plasma albumin level and 
prothrombin time were within or just above the normal range. 
Therefore, there was only minimal hepatocellular damage 
and impairement of liver function in the non-cirrhotic group. 
The plasma creatinine level was higher in the cirrhotic group 
compared with the non-cirrhotic group, although the differ-
ence was not significant due to the high intra‑group variation. 
The mean plasma 7B2-IR concentration in liver disease was 
99.44±15.9 pmol/l. In the patients with hepatocellular damage 
due to metastatic tumours [Ca bronchus, carcinoid (n=6)], 
the 7B2-IR concentrations were higher [185±36.9 pmol/l, 
(P<0.05)] compared with the overall subjects with liver 
damage (Fig. 1).
When the 11 patients with other causes of liver damage 
were screened separately, the mean plasma 7B2-IR concentra-
tion was 56.68±4.5 pmol/l.
Chromatography. Fig. 2 shows a representative 7B2 plasma 
chromatographic profile from the patients with liver damage.
Discussion
In the present study, it was observed that 7B2-IR levels were 
increased in liver disease. In the majority of the patients with 
hepatocellular damage, the 7B2-IR levels ranged between 
1.5- and 3-fold of the normal range compared with the control 
subjects. These data are in accordance with previous studies 
that have demonstrated increased 7B2 plasma levels in patients 
with cirrhosis (28). Kobori (35) also reported increased 7B2-IR 
in the plasma of 13 patients with cirrhosis.
In the present study, it was also evident that in individual 
patients with liver disease due to metastatic tumours (Ca bron-
chus, metastatic carcinoid), 7B2-IR was increased by >3-5-fold 
compared with the normal range. This agrees with the results 
of Suzuki et al (36) who showed that 7B2-IR is mainly encoun-
tered in neoplastic conditions, particularly endocrine or other 
tumours of the gastrointestinal tract. It is therefore difficult to 
conclude whether 7B2 is produced by the damaged hepatocyte 
or if it is released by the tumour itself, particularly for patients 
with liver damage due to metastatic tumours.
The immunocytochemical analysis of tumour tissues 
has revealed more extensive associations between 7B2 and 
neuroendocrine tumours than the titration of its circulating 
levels. 7B2 has been detected in the majority of benign, and 
approximately half of malignant, pancreatic tumours, particu-
larly insulin-producing tumours (36-39). Notably, insulinomas 
containing only proinsulin and not the active mature form 
were shown to also lack 7B2 (38). 7B2-IR has been detected in 
bronchial carcinoids and small-cell lung carcinomas that are 
associated with liver metastases (36,39-41).
Various other neuropeptides have been investigated in liver 
diseases and alterations in their levels have been observed. 
Neurotensin (NT) is expressed in the human fetal liver, but 
not in adults. NT is also expressed in fibrolamellar carcinoma, 
although it is not expressed in the regenerating rat liver (42). NT 
has also been shown to be produced by a fibrolamellar hepa-
toma (14). The majority of liver tumours express cholecystokinin 
(CCK-B) receptors and are able to process gastrin (G) as far as 
pro-G and G-gly (the precursor forms), which may be associ-
ated with tumour proliferation (43,44). Gut hormone receptors 
are overexpressed in human cancer and allow receptor-targeted 
tumour imaging and therapy. A novel promising receptor for 
these purposes is the secretin receptor. Secretin receptors are 
expressed in the human liver, particularly in the biliary tract 
and cholangiocarcinomas, but not in hepatocytes or hepato-
cellular carcinomas (19). Hepatic failure is associated with 
increased pancreatic glucagon levels (true hyperglucagonaemia 
suppressed by glucose) (20). Methionine-enkephalin and other 
opioid peptides have been shown to be increased in cirrhosis 
and acute liver disease (23). Additionally, there is evidence that 
the central mechanism involved in the brain-liver interaction in 
the development of the symptoms of hepatic encephalopathy 
(such as pruritus and fatigue) involves the opioid system (23,44). 
A class of endogenous opioids is upregulated in liver disease, 
particularly cholestasis, which contribute to pruritus, hypoten-
sion and encephalopathy. Symptoms associated with cholestasis 
are reversed or at least ameliorated by mu-opioid receptor 
antagonists. Opioid receptor antagonists have been reported 
to relieve multiple symptoms, with the exception of pruritus, 
and improve liver function, as demonstrated in experimental 
cholestasis (23,44). In a multiple primary hepatic carcinoid 
tumour of the liver, neuron‑specific enolase (NSE) and chro-
mogranin were identified immunocytochemically in all tumour 
cell types. The S-100 protein, human choriogonadotrophin 
and serotonin were also observed (45). It has been suggested 
previously that 7B2-IR is co-localised with several chromo-
granins in the secretory granules (44,45) and that it belongs to 
the granin family (46). It is therefore possible that, in patients 
whose disease is due to primary or secondary liver neoplasms, 
7B2-IR levels may be even higher than in cirrhosis of other 
aetiologies, due to the overproduction of 7B2 by the tumour 
cells, as observed in several liver neoplasms that have been 
positively stained for chromogranin peptides (47,48).
Figure 2. Representative plasma 7B2 chromatographic profile obtained from 
patients with liver disease. The column was calibrated with Vo, CC and Vt 
as molecular size markers. Vo, Dextran blue; CC, horse heart cytochrome C; 
Vt, Na 125.
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In neuroendocrine cells, 7B2 functions as a specific chap-
erone for proprotein convertase 2 (proPC2) (49). It has been 
proposed that 7B2 serves as an intracellular proPC2 chaperone 
and prevents the premature activation of the zymogen during 
its transit in the regulated secretory pathway. It appears that 
pro7B2 attaches to proPC2 in the endoplasmic reticulum 
(ER). This attachment is facilitated by the relatively alkaline 
conditions of this compartment. The inactive complex is 
transported to the trans-Golgi network (TGN) where pro7B2 
is cleaved into an N-terminal protein and a C-terminal peptide. 
ProPC2 is then autocatalytically cleaved after the prodomain 
as the complex is transported into secretory granules. In these 
organelles, the prodomain and 7B2 fragments dissociate from 
the enzyme, which then becomes fully activated. Thus, 7B2 
regulates PC2 activation (49). The 7B2 and PC2 proteins are 
packaged into secretory granules. It is unclear whether proPC2 
requires an association with 7B2 polypeptides in order to be 
sorted into these organelles. Although not yet established, 7B2 
may be a component of the PC2 aggregates that are sorted into 
the secretory granules (50,51).
Since 7B2 has been grouped with the chromogranins and 
secretogranins into the so-called granin family of proteins, 
one of its presumed functions is to facilitate the sorting of 
neuroendocrine proteins from the secretory granules (46). 
By studying POMC-expressing non-pituitary tumours, corti-
cotrophin-like-intermediate lobe peptide (CLIP), a product 
of corticotrophin cleavage by PC2, was detected only in the 
tumours that expressed PC2 (39,51), and it may be assumed 
that these tumours also contain 7B2. 
7B2 has also been detected in pituitary tumours (52,53). It 
is also noteworthy that, unlike PC2-null mice which are viable, 
7B2-null mutants die early in life from Cushing's disease due 
to ACTH hypersecretion by the intermediate lobe, suggesting 
the possible involvement of 7B2 in secretory granule formation 
and secretion regulation (54). The 7B2-null mice with Cushing's 
disease may be saved early in life by an adrenalectomy (55). 
Neither our plasma ACTH tumours of Cushing's patients (26,56), 
nor those studied by Natori et al (57,58) allow the conclusion 
that 7B2-IR levels in plasma are increased in Cushing's patients, 
and corticotrophic adenomas have not shown increased 7B2 
secretion in vitro, although 7B2 is concomitantly secreted with 
ACTH by AtT-20 tumourous cells in vitro (56). It has been 
suggested that the lethal phenotype that is exhibited by 7B2-null 
mice with a complex Cushing's disease-like pathology, is due 
to intermediate lobe ACTH hypersecretion as a consequence of 
the interruption of PC2-mediated peptide processing, as well as 
undefined consequences of the loss of 7B2. 
Sarac et al (59) reported that 7B2-null mice exhibit a 
multisystem disorder that includes severe pathoanatomical 
and histopathological alterations to vital organs, including 
the heart and spleen, but most notably the liver, in which 
massive steatosis and necrosis are observed. Metabolic 
derangements in the glucose metabolism result in glycogen 
and fat deposition in the liver under conditions of chronic 
hypoglycaemia. Liver failure is also likely to contribute to 
abnormalities in blood coagulation and blood chemistry, such 
as lactic acidosis. It has been suggested that a hypoglycaemic 
crisis coupled with respiratory distress and intensive internal 
thrombosis is likely to result in the rapid deterioration and 
death of the 7B2-null mice (59).
All the aforementioned observations and knowledge make 
7B2 an intriguing molecule, whose definite function remains 
to be elucidated in view of the fact that it appears to exist in 
cells where PC2 activity is not evident (60), thus suggesting a 
bigger biological role for 7B2 compared with PC2.
The family of proprotein convertases has been implicated 
in tumourigenesis and metastasis in animal models. In a study 
assessing PC1, PC2 and 7B2 in primary colon cancers, PC1 
and PC2 mRNA, protein expression and protein cleavage 
profiles were observed to be altered in liver colorectal metas-
tases compared with unaffected and normal livers. Active PC1 
protein was overexpressed in tumours, which correlated with 
its mRNA profile. Moreover, the enhanced PC2 processing 
pattern in the tumours was correlated with the overexpression 
of its specific binding protein 7B2. These results were corrobo-
rated by immunocytochemistry. The authors suggested that the 
exclusive presence of 7B2 in metastatic tumours may represent 
a new target for early diagnosis, prognosis and/or treatment (61).
Liver dysfunction may be due to various pathologies and 
drug interactions, and all the aforementioned observations 
suggest that 7B2 may be have a more biologically important 
role than PC2. The biological role of 7B2 appears to be 
important for animal survival, and more studies should be 
undertaken to identify a definite role for this protein, not only 
in liver disease, but also in other clinical entities.
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